Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $3.4 million.

  • Ptc Therapeutics' Capital Expenditures rose 55996.17% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 2351.52%. This contributed to the annual value of $6.5 million for FY2024, which is 7713.62% down from last year.
  • Per Ptc Therapeutics' latest filing, its Capital Expenditures stood at $3.4 million for Q3 2025, which was up 55996.17% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Capital Expenditures peaked at $10.3 million during Q1 2023, and registered a low of -$7.4 million during Q2 2024.
  • For the 5-year period, Ptc Therapeutics' Capital Expenditures averaged around $5.4 million, with its median value being $5.8 million (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 21809.45% in 2024, then soared by 55996.17% in 2025.
  • Ptc Therapeutics' Capital Expenditures (Quarter) stood at $8.7 million in 2021, then decreased by 1.19% to $8.6 million in 2022, then plummeted by 35.44% to $5.6 million in 2023, then plummeted by 32.32% to $3.8 million in 2024, then dropped by 8.55% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.7 million during Q1 2025.